
What opponents of the EU-US trade deal get wrong
The deal is certainly unlike any other the EU has struck before. Exports to America will face a tariff of 15%, lower than the 30% that had been threatened had no deal been struck, but nearly ten times as high as the rate that prevailed before Mr Trump returned to the White House. In turn, the EU will eliminate its own tariffs on imports of American industrial goods, and provide easier access for some farm produce. The bloc is also expected to buy more energy from America, and invest hundreds of billions across the Atlantic. For those who see trade as a zero-sum game in which deficits are for losers and exporters are winners, the EU got fleeced.
The naysayers are misguided, however. Unfortunately, Mr Trump's love of tariffs means the old days of low duties are not coming back while he is in power. And the deal is not as catastrophic as its critics claim. The EU has secured similar terms to Japan's, so its relative trading position remains the same. Cars made in Europe will no longer face higher, sectoral duties. And the EU has not had to surrender its plans to regulate digital services, which mainly hit America's tech giants.
Some bemoan the asymmetry of the deal; that European manufacturers face tariffs, while Americans gain market access. But trade is not a zero-sum game. European consumers will benefit from greater choice and lower prices, whereas the bulk of the tariff cost will be borne by American businesses and shoppers, even if some foreign firms do cut their prices.
Last, the broader geopolitical context meant that escalation was never an attractive option for the EU. If trade were the only thing on the agenda, the bloc could have better afforded to hit back, in the hope of forcing America to relent. But 'it is [also] about security, it is about Ukraine,' Maros Sefcovic, the EU's trade commissioner, has said about the negotiations. Because Europe has for decades outsourced its security to America, it needed to offer trade terms that would keep a mercurial president happy and willing to stay engaged in Europe.
The EU's critics ignore the fact that its problems run deeper than a single trade deal. The economy badly needs reform, innovation and investment, as Mario Draghi, a former head of the European Central Bank, laid out in a colossal report in 2024. Mr Trump's 15% transatlantic tariff pales in comparison with the cost of internal trade frictions; the IMF reckons barriers within the eu amount to a staggering 44% tariff on goods and 110% on services. Europe's capital markets are too shallow and fragmented to fund risky, innovative ideas. And the continent is far from adding the extra investments needed to close the productivity gap.
Rather than focusing on what America is doing wrong, the EU should look closer to home. Member states are stymieing reform. Germany is loth to boost its own capital markets, let alone integrate capital markets across Europe. France is the biggest obstacle to making more trade deals that would help diversify exporters' markets. Almost a year since the Draghi report, barely any of its recommendations have been acted on. Damaging as a trade war would have been, it might at least have shaken politicians out of their torpor. Instead of pointing fingers, the critics should roll up their sleeves.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
4 minutes ago
- Economic Times
US' new tariff list: India at 25%, exports to get hit, competitors in lower band
Synopsis Effective August 7, 2025, the US has imposed a blanket 25% tariff on all Indian-origin goods, placing India among the most harshly treated nations in its new tariff regime. This measure, part of a new Executive Order, denies India product-level exemptions, even for critical sectors like pharmaceuticals and electronics. Agencies US' new tariff list New Delhi: In a move that could dent India's exports to US, Washington has imposed a blanket 25% tariff on all Indian-origin goods, effective August 7, measure, part of a new Executive Order issued by US President Donald Trump on July 31, places India among the most harshly treated countries in the new American tariff regime, offering no product-level exemptions even for sectors deemed critical like pharmaceuticals, energy, and Order mentions that tariffs may be reduced once countries do a deal with the per the order, countries have been subject to tariffs ranging from 10% to over 41% with differential rates based on geopolitical risk, economic alignment, and trade said the new order puts India at disadvantage to majority competitors including Pakistan, Vietnam, Bangladesh, Turkey where the tariffs are 15-20%. 'India's exports of petroleum products, smartphones, pharmaceuticals, engineering goods, electronics, and textiles will bear the brunt of the tariffs,' said a representative of an export promotion penalty threatened by Trump on India for doing business with Russia has not yet been US, Wednesday, announced 25% tariffs on India along with undisclosed penalty on trading with Russia.'The implications of the recent development are being examined by the government. The Ministry of Commerce and Industry is engaged with all stakeholders including exporters and industry for taking feedback of their assessment of the situation,' commerce and industry minister Piyush Goyal said in his statement in Parliament US was India's largest export destination in FY25 with shipments valued at $86.51 billion. But it accounted for less than a fifth of its total goods exports of $437.42 per the Order, unlike many other trading partners, India has been denied all product-level exemptions—even for products and sectors, the US exempted Goods from other tariff exempted categories include finished pharmaceutical drugs, APIsand other key drug inputs; energy products, critical minerals and a wide range of electronics and EU has been granted a special concession in which if the existing US most favoured nation (MFN) tariff on an EU product is below 15%, the total tariff will be increased to 15%. However, if the MFN tariff is already 15% or higher, then no additional duty will be charged.A 10% tariff applies to a few countries—Brazil, the UK, and the Falkland 15% tariff, which is the most common, covers 38 countries. Countries facing higher tariffs (25-30%) include India, Brunei, Kazakhstan, Moldova, and and Serbia at 35%, Switzerland at 39% (unusually high for a developed nation), Laos and Myanmar at 40%, and Syria at 41%, the US Customs Border Protection authority will realise a guidance clarifying on how this measure will be applied.


Hans India
7 minutes ago
- Hans India
Trump asks 17 non-Indian drug majors to cut prices in US; Nifty pharma dips
Mumbai: A letter from US President Donald Trump has asked 17 global drug giants to cut their prices in the country, sparking severe losses for them, as its impact hit the Indian stock market too. The letter urged that these businesses cut US drug pricing to match prices in other developed markets. Though no Indian pharmaceutical companies received Trump's letters, the Nifty Pharma index reacted sharply, falling 2.45 per cent during the intra-day trade on Friday. The index fell for the third day in a row. Sun Pharmaceutical Industries Ltd fell 3.98 per cent. Aurobindo Pharma lost 3.42 per cent and Granules India lost 3.2 per cent. Gland Pharma, Cipla, and Lupin fell 2 to 3 per cent. The US President wrote to 17 of the world's major pharmaceutical corporations, pressing them to lower drug prices immediately and give assurance that future drugs will be priced in line with other countries. The letters were sent to Eli Lilly, Novo Nordisk, Pfizer, and others, seeking 'Most Favoured Nation' (MFN) pricing for US within 60 days. White House Press Secretary Karoline Leavitt said recent data showed that Americans paid more than three times more for brand-name drugs than other developed nations. Trump had earlier made a similar announcement on May 12, asking pharma companies to cut prices in US. Industry sources in India had then said Trump's proposal might hurt Indian exporters of branded generics to the US, given generic drugs are already sold at low prices. If prices are cut further, it will make shipping unviable, they said. A third of Indian pharmaceutical exports of $30 billion annually, reach the US market. Trump gave drug companies 60 days to voluntarily comply with the new pricing diktat in the letter, failing which, he said, the US would use 'every tool in our arsenal' to protect Americans from 'continued abusive drug pricing' practices. Trump's letter required companies to sell certain drugs directly to patients at prices at which they are offered to third-party insurers.


News18
7 minutes ago
- News18
Joe Biden Warns 'These Are Dark Days' In Address At National Bar Association Gala Trump
Former U.S. President Joe Biden delivered a forceful speech at the National Bar Association's 100th annual gala in Chicago on July 31, 2025, warning that civil rights, the judiciary, and marginalized communities now face existential threats under the Trump administration. Speaking to an audience of nearly 1,100 Black legal professionals, Biden decried rollbacks to immigration protections, erosion of legal precedents, and law firms capitulating to political pressure. He framed the moment as the most dire since the 1960s civil rights era and urged resilience in the defense of American values and institutions. Mobile App -